In this context, this narrative review presents an overview of preclinical and clinical studies that support a role of the NLRP3 inflammasome in the pathogenesis of MDD, highlighting that pathways related to NLRP3 inflammasome represent promising strategies for the treatment of this mood disorder. Here, NLRP3 is linked to major depressive disorder.